200 related articles for article (PubMed ID: 30371224)
1. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study.
Kuo KL; Hung SC; Tseng WC; Tsai MT; Liu JS; Lin MH; Hsu CC; Tarng DC;
J Am Heart Assoc; 2018 Aug; 7(15):e009206. PubMed ID: 30371224
[TBL] [Abstract][Full Text] [Related]
2. Association of anemia and iron parameters with mortality among prevalent peritoneal dialysis patients in Taiwan: the AIM-PD study.
Kuo KL; Liu JS; Lin MH; Hsu CC; Tarng DC;
Sci Rep; 2022 Jan; 12(1):1269. PubMed ID: 35075212
[TBL] [Abstract][Full Text] [Related]
3. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
[TBL] [Abstract][Full Text] [Related]
6. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
[TBL] [Abstract][Full Text] [Related]
7. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
8. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
[TBL] [Abstract][Full Text] [Related]
9. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
[TBL] [Abstract][Full Text] [Related]
10. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
[TBL] [Abstract][Full Text] [Related]
11. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
[TBL] [Abstract][Full Text] [Related]
12. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
13. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
15. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
16. Different Effects of Iron Indices on Mortality in Patients With Autosomal Dominant Polycystic Kidney Disease After Long-Term Hemodialysis: A Nationwide Population-Based Study.
Yeh SC; Lin YC; Hong YC; Hsu CC; Lin YC; Wu MS
J Ren Nutr; 2019 Sep; 29(5):444-453. PubMed ID: 30683605
[TBL] [Abstract][Full Text] [Related]
17. The treatment effects and cardiovascular events of high-dose intravenous iron for hemodialysis patients with renal anemia: A systematic review and meta-analysis.
Zhang S; Ouyang M; Liu L
Chronic Illn; 2024 Jun; 20(2):221-232. PubMed ID: 37282508
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
[TBL] [Abstract][Full Text] [Related]
19. Cost savings using a protocol approach to manage anemia in a hemodialysis unit.
Charlesworth EC; Richardson RM; Battistella M
Am J Nephrol; 2014; 39(6):509-14. PubMed ID: 24903565
[TBL] [Abstract][Full Text] [Related]
20. Effect of anemia and hyperhomocysteinemia on mortality of patients on hemodialysis.
Anees M; Mumtaz A; Ibrahim M; Shaheen SM; Asghar A
Iran J Kidney Dis; 2010 Jan; 4(1):60-5. PubMed ID: 20081306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
